Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00012155
First received: March 3, 2001
Last updated: June 25, 2013
Last verified: November 2002
  Purpose

RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I trial to study the safety of NV1020 in patients who have colon cancer that has spread to the liver and has not responded to previous chemotherapy.


Condition Intervention Phase
Colorectal Cancer
Metastatic Cancer
Biological: NV1020
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I, Open-Label, Dose-Escalating Study Of The Safety, Tolerability, And Anti-Tumor Activity Of A Single Intrahepatic Arterial Injection Of Genetically Engineered Herpes Simplex Virus, NV1020, In Subjects With Adenocarcinoma Of The Colon With Metastasis To The Liver

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Study Start Date: October 2000
Study Completion Date: December 2009
Primary Completion Date: November 2002 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Determine the safety and maximum tolerated dose of a single intrahepatic NV1020 injection in patients with hepatic metastases from colon cancer that has failed first-line chemotherapy.
  • Determine the tolerability of this drug in these patients.
  • Determine preliminarily the anti-tumor activity of this drug in these patients.
  • Assess the immunogenicity of NV1020 in these patients.

OUTLINE: This is a dose escalation study.

Patients receive a single intrahepatic arterial injection of NV1020 over 10 minutes with the aid of hepatic arteriography.

Cohorts of 3 patients receive escalating doses of NV1020 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 patients experience dose-limiting toxicity.

Patients are followed at 1, 2, and 3 months post injection. Patients may participate in a separate long term (up to 1 year) follow-up study for continued assessment and monitoring.

PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the colon

    • At least 3 metastatic hepatic lesions involving both lobes
    • No extrahepatic disease
  • Failed first-line combination chemotherapy of fluorouracil plus either leucovorin calcium or irinotecan
  • Herpes simplex virus type-1 seropositive
  • Candidate for intrahepatic arterial infusion pump placement

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • Not specified

Hematopoietic:

  • WBC greater than 3,000/mm^3
  • Absolute neutrophil count greater than 1,500/mm^3
  • Platelet count greater than 100,000/mm^3
  • Hemoglobin greater than 9.0 g/dL
  • No history of any blood clotting disorder (e.g., hemophilia)

Hepatic:

  • Transaminases no greater than 3 times upper limit of normal
  • Bilirubin no greater than 2.0 mg/dL
  • No active hepatitis
  • No history of hepatic fibrosis, cirrhosis, or hemochromatosis

Renal:

  • Creatinine no greater than 2.0 mg/dL

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • All patients must use effective barrier contraception during and for at least 6 months after study
  • HIV negative
  • No active herpes infection
  • No other active uncontrolled infection
  • No prior weight loss of more than 10 lbs within the past month
  • No history of alcohol or other substance abuse
  • No concurrent unstable and/or severe medical or psychological condition
  • No history of any other medical or psychological condition that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • At least 4 weeks since prior immunotherapy (e.g., interleukin-2, interleukin -12, or interferon)
  • No prior gene transfer therapy
  • No prior therapy with cytolytic virus of any type
  • No concurrent immunotherapy during and for 28 days after study therapy
  • No concurrent vaccines during and for 28 days after study therapy

Chemotherapy:

  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
  • No concurrent chemotherapy during and for 28 days after study therapy

Endocrine therapy:

  • No concurrent systemic steroids during and for 28 days after study therapy

Radiotherapy:

  • No prior radiotherapy to the liver
  • No concurrent radiotherapy during and for 28 days after study therapy

Surgery:

  • At least 2 weeks since prior surgery

Other:

  • At least 30 days since prior participation in investigational study
  • No concurrent antiviral agent active against herpes simplex virus (e.g., acyclovir, valacyclovir, penciclovir, famciclovir, ganciclovir, foscarnet, or cidofovir) during and for 28 days after study therapy
  • No concurrent immunosuppressive agents (e.g., cyclosporine) during and for 28 days after study therapy
  • No other concurrent investigational or anti-cancer agents during and for 28 days after study therapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00012155

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Study Chair: Yuman Fong, MD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
Publications:
Kemeny N, Jarnagin W, Guilfoyle B, et al.: Results of a phase I, dose-escalating study of the safety, tolerability and anti-tumor activity of a single injection of a genetically engineered herpes simplex virus, nv1020, in subjects with hepatic colorectal metastases. [Abstract] Ann Oncol 16 (Suppl 2): A-480, ii283, 2005.

ClinicalTrials.gov Identifier: NCT00012155     History of Changes
Other Study ID Numbers: MSKCC-00022, CDR0000068488, MGENE-NR1-001, NCI-G01-1920
Study First Received: March 3, 2001
Last Updated: June 25, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage IV colon cancer
recurrent colon cancer
adenocarcinoma of the colon
liver metastases

Additional relevant MeSH terms:
Adenocarcinoma
Colonic Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Neoplasms
Neoplasms, Second Primary
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on April 17, 2014